AVXL•benzinga•
Anavex Life Sciences Q1 2025 GAAP EPS $(0.14) Beats $(0.19) Estimate, Cash And Cash Equivalents Of $120.8M At December 31, 2024, The Company Anticipates At Current Cash Utilization Rates And Ranges, A Runway Of Approximately 4 Years
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga